Arizona Center for Advanced Medicine offers Amyloid Beta (Aβ) screening, which research has shown to have a 90% accuracy in detecting Alzheimer’s disease, as part of our medical services for individuals and families in Scottsdale and its surrounding areas. The primary screening method is a simple blood test that we perform through a patient-funded study in association with the Young Blood Institute, a 501 (c) (3) non-profit clinical research organization studying new indications for therapeutic plasma exchange. Our doctors can recommend additional screening depending on your results and possible treatment options if necessary.
This screening costs a little under $1,000 and getting an early diagnosis can make a critical difference in your chances of successful treatment. We are dedicated to empowering you with all necessary information so you can play an active role in your well-being. Our staff members are here to answer any questions you may have about the screening or your treatment plan.
Our Amyloid Beta (Aβ) screening at Arizona Center for Advanced Medicine uses a simple blood test to check your levels of amyloid-beta plaque. Scientific research has shown that this test has an accuracy of greater than 90% in detecting sufficiently high levels of this substance to predict the likelihood of contracting Alzheimer’s disease.
If your results indicate excessive levels of amyloid-beta plaque, our doctors can order diagnostic image testing, usually a PET scan. This additional test, can help to visually confirm the presence of amyloid plaque in your brain.
When both tests confirm high levels of amyloid-beta plaque in the bloodstream and the brain, we can create a treatment plan for using plasma exchange to remove Amyloid Beta (Aβ) plaques, with the intention of stopping the progression of Alzheimer’s disease or preventing it altogether. For those who have concerns about cognitive decline, we can incorporate standardized cloud-based software testing to assess your level of cognitive impairment. This standardized instrument assesses orientation, language, memory, praxis, attention, abstract thinking, perception and calculation. For those with no signs of cognitive impairment but having high levels of Amyloid Beta (Aβ) plaques, we can use plasma exchange as a treatment modality to attempt to remove or halt further development of the plaques and prevent or mitigate any development of cognitive impairment.